K
Kenna Anderes
Researcher at Pfizer
Publications - 63
Citations - 4088
Kenna Anderes is an academic researcher from Pfizer. The author has contributed to research in topics: Cancer & Kinase. The author has an hindex of 24, co-authored 55 publications receiving 3455 citations. Previous affiliations of Kenna Anderes include Novo Nordisk.
Papers
More filters
Journal ArticleDOI
Anticancer Activity of CX-3543: A Direct Inhibitor of rRNA Biogenesis
Denis Drygin,Adam Siddiqui-Jain,Sean O'Brien,Michael K. Schwaebe,Amy M. Lin,Josh Bliesath,Caroline B. Ho,Chris Proffitt,Katy Trent,Jeffrey P. Whitten,John K.C. Lim,Daniel D. Von Hoff,Kenna Anderes,William G. Rice +13 more
TL;DR: CX-3543 is the first G-quadruplex interactive agent to enter human clinical trials, and it is currently under evaluation against carcinoid/neuroendocrine tumors in a phase II clinical trial.
Journal ArticleDOI
Targeting RNA Polymerase I with an Oral Small Molecule CX-5461 Inhibits Ribosomal RNA Synthesis and Solid Tumor Growth
Denis Drygin,Amy M. Lin,Josh Bliesath,Caroline B. Ho,Sean O'Brien,Chris Proffitt,Mayuko Omori,Mustapha Haddach,Michael K. Schwaebe,Adam Siddiqui-Jain,Nicole Streiner,Jaclyn E Quin,Elaine Sanij,Megan J. Bywater,Ross D. Hannan,David M. Ryckman,Kenna Anderes,William G. Rice +17 more
TL;DR: Molecular studies demonstrate that CX-5461 inhibits the initiation stage of rRNA synthesis and induces both senescence and autophagy, but not apoptosis, through a p53-independent process in solid tumor cell lines.
Journal ArticleDOI
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.
Megan J. Bywater,Gretchen Poortinga,Gretchen Poortinga,Elaine Sanij,Elaine Sanij,Nadine Hein,Abigail Peck,Carleen Cullinane,Meaghan Wall,Leonie A. Cluse,Denis Drygin,Kenna Anderes,Nanni Huser,Chris Proffitt,Josh Bliesath,Mustapha Haddach,Michael K. Schwaebe,David M. Ryckman,William G. Rice,Clemens A. Schmitt,Clemens A. Schmitt,Scott W. Lowe,Ricky W. Johnstone,Ricky W. Johnstone,Richard B. Pearson,Grant A. McArthur,Ross D. Hannan +26 more
TL;DR: It is shown that rDNA transcription can be therapeutically targeted with the small molecule CX-5461 to selectively kill B-lymphoma cells in vivo while maintaining a viable wild-type B cell population.
Journal ArticleDOI
CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
Adam Siddiqui-Jain,Denis Drygin,Nicole Streiner,Peter C. Chua,Fabrice Pierre,Sean O'Brien,Josh Bliesath,Mayuko Omori,Nanni Huser,Caroline B. Ho,Chris Proffitt,Michael K. Schwaebe,David M. Ryckman,William G. Rice,Kenna Anderes +14 more
TL;DR: CX-4945 is the first orally bioavailable small molecule inhibitor of CK2 to advance into human clinical trials, thereby paving the way for an entirely new class of targeted treatment for cancer.
Journal ArticleDOI
Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer.
Fabrice Pierre,Peter C. Chua,Sean O'Brien,Adam Siddiqui-Jain,Pauline Bourbon,Mustapha Haddach,Jerome Michaux,Johnny Y. Nagasawa,Michael K. Schwaebe,Eric Stefan,Anne Vialettes,Jeffrey P. Whitten,Ta Kung Chen,Levan Darjania,Ryan Stansfield,Kenna Anderes,Josh Bliesath,Denis Drygin,Caroline B. Ho,May Omori,Chris Proffitt,Nicole Streiner,Katy Trent,William G. Rice,David M. Ryckman +24 more
TL;DR: The discovery of CX-4945 (25n), a first-in-class, orally bioavailable ATP-competitive inhibitor of protein kinase CK2 in clinical trials for cancer, will allow the therapeutic targeting of CK1 in humans for the first time.